Business
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
– 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs – Sufficient capital to fund
About this update from Moleculin Biotech, Inc.
[{"type":"text","content":"– 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs\n– Sufficient capital to fund operations into the third quarter of 2024\n– Company to host conference call and webcast today at 8:30 AM ET\nHOUSTON, March 23, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (\"Moleculin\" or the \"Company\"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2022 and provided a pipeline update. As previously announced, the Company will host a conference call and live audio webcast, today, Thursday, March 23, 2023, at 8:30 AM ET (details below).\n\n \n \n \n \n \n \n\n \n\"I am extremely proud of our team's solid execution of our strategy in 2022, resulting in significant progress on multiple fronts. We fully expect to build on the momentum from our positive and highly encouraging data to date and believe Moleculin is well positioned for an exciting 2023. Specifically, we look forward to multiple data readouts with Annamycin as well as across our pipeline over the course of this year, which we hope will unlock value in the near and long term,\" commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin.\nRecent Highlights \nAnnounced the publication of data evaluating Annamycin's performance as an anthracycline designed to avoid the cardiotoxicity typically associated with currently prescribed anthracyclines, in a manuscript titled, \"Anthracycline-induced cardiotoxicity – are we about to clear this hurdle?,\" published in the peer-reviewed European Journal of Cancer.Received approval in Italy to conduct and dosed first subjects for Phase 1/2 trial evaluating Annamycin in combination with cytarabine (Ara-C) for the treatment of acute myeloid leukemia (AML).Announced final topline successful safety data – setting a recommended Phase 2 dose - and reported 80% overall response rate in final cohort from the European Phase 1 trial evaluating Annamycin as a single agent treatment of Refractory AML.Granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) of WP1122 for the treatment of Glioblastoma Multiforme (GBM).Summary of Financial Results for the Full Year 2022 \nR...